The list below contains links to the European Medicines Agency. Through this website, you will find links to the European Public Assessment Report (EPAR) as well as the Patient Information Leaflets (PIL) and Summary of Product Characteristics (SPC) for our licensed product Translarna ▼ (ataluren).

Please note that this information is not intended to replace the advice of a qualified healthcare professional.

Translarna (ataluren)   EPAR
Translarna (ataluren) SmPC PIL


▼ This medicinal product is subject to additional monitoring. Adverse events (suspected side effects) should be reported. Healthcare professionals and patients are asked to report any suspected adverse events via the Yellow Card Scheme. Reporting forms and information can be found at

Adverse events can also be reported to PTC Therapeutics Ltd at

By following this link you will be leaving the website.

Please note that PTC Therapeutics Limited does not take responsibility for the content displayed on other websites.
Cancel Continue